Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma.
Matsumoto Y, Chinen Y, Shimura Y, Nagoshi H, Sasaki N, Muramatsu A, Kuriyama K, Ohshiro M, Hirakawa Y, Iwai T, Uchiyama H, Taki T, Horiike S, Kuroda J, Taniwaki M. Matsumoto Y, et al. Among authors: sasaki n. Int J Hematol. 2020 Jan;111(1):75-83. doi: 10.1007/s12185-019-02766-z. Epub 2019 Nov 4. Int J Hematol. 2020. PMID: 31686349
Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N, Kuroda J, Nagoshi H, Yamamoto M, Kobayashi S, Tsutsumi Y, Kobayashi T, Shimura Y, Matsumoto Y, Taki T, Nishida K, Horiike S, Akao Y, Taniwaki M. Sasaki N, et al. Exp Hematol. 2011 Aug;39(8):817-28.e1. doi: 10.1016/j.exphem.2011.05.002. Epub 2011 May 11. Exp Hematol. 2011. PMID: 21640157 Free article.
Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma.
Matsumoto Y, Tsukamoto T, Chinen Y, Shimura Y, Sasaki N, Nagoshi H, Sato R, Adachi H, Nakano M, Horiike S, Kuroda J, Taki T, Tashiro K, Taniwaki M. Matsumoto Y, et al. Among authors: sasaki n. J Clin Exp Hematop. 2021 Jun 5;61(2):71-77. doi: 10.3960/jslrt.20033. Epub 2021 Apr 20. J Clin Exp Hematop. 2021. PMID: 33883344 Free PMC article.
Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis.
Matsumoto Y, Horiike S, Ohshiro M, Yamamoto M, Sasaki N, Tsutsumi Y, Kobayashi T, Shimizu D, Uchiyama H, Kuroda J, Nomura K, Shimazaki C, Taniwaki M. Matsumoto Y, et al. Among authors: sasaki n. Am J Clin Pathol. 2010 Feb;133(2):281-90. doi: 10.1309/AJCP0SBHYVLY5EML. Am J Clin Pathol. 2010. PMID: 20093238
Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome.
Mizutani S, Kuroda J, Shimura Y, Kobayashi T, Tsutsumi Y, Yamashita M, Yamamoto M, Ohshiro M, Sasaki N, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Nakamura S, Taniwaki M. Mizutani S, et al. Among authors: sasaki n. Acta Haematol. 2011;126(1):8-12. doi: 10.1159/000323565. Epub 2011 Mar 17. Acta Haematol. 2011. PMID: 21411984
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Kiyota M, et al. Among authors: sasaki n. Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17. Int J Hematol. 2012. PMID: 22426624
Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients.
Sasaki N, Shimura K, Yoshida M, Uoshima N, Kiyota M, Hatsuse M, Uchiyama H, Chinen Y, Kobayashi T, Nakao M, Takahashi R, Nakano-Akamatsu S, Kaneko H, Kobayashi Y, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) investigators. Sasaki N, et al. Int J Hematol. 2019 Mar;109(3):278-285. doi: 10.1007/s12185-018-02583-w. Epub 2019 Jan 9. Int J Hematol. 2019. PMID: 30627868 Clinical Trial.
Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
Isa R, Uoshima N, Takahashi R, Nakano-Akamatsu S, Kawata E, Kaneko H, Shimura K, Kamitsuji Y, Takimoto-Shimomura T, Mizutani S, Chinen Y, Ohshiro M, Fujino T, Kawaji Y, Uchiyama H, Sasaki N, Tsukamoto T, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Isa R, et al. Among authors: sasaki n. Ann Hematol. 2020 Jan;99(1):137-145. doi: 10.1007/s00277-019-03859-9. Epub 2019 Nov 25. Ann Hematol. 2020. PMID: 31768675 Clinical Trial.
2,440 results